Recent Updates
Recently added Catalysts
REGN

Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth Blocking Delta-like Ligand 4 May Benefit Patients with Tumors Resistant to Other Anti-Angiogenesis Therapies Regeneron’s VelocImmune Technology Used to Create Fully Human Antibody

Friday, December 22, 2006 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth Blocking Delta-like Ligand 4 May Benefit Patients with Tumors Resistant to Other Anti-Angiogenesis Therapies Regeneron’s VelocImmune Technology Used to Create Fully Human Antibody

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+42%
120-day peak, hindsight
Typical move
2.7%
average across 15 past catalysts
Lead asset
REGN7508
Phase 3 · Venous Thromboembolism

Full Press Release Details

Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth Blocking Delta-like Ligand 4 May Benefit Patients with Tumors Resistant to Other Anti-Angiogenesis Therapies Regeneron’s VelocImmune Technology Used to Create Fully Human Antibody.

Biotech snapshot

Cash runway
$17823M liquidity · $0M/mo burn
Low dilution risk
Lead asset
REGN7508Phase 3
Venous Thromboembolism →

Catalyst track record

+42%
best trade around REGN's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for REGN.

See every catalyst's timing & PoA →